Welcome to LookChem.com Sign In|Join Free
  • or
Methyl syringate, a benzoate ester obtained by the formal condensation of the carboxy group of syringic acid with methanol, is a beige powder with unique chemical properties. It is known for its role in the volatile compound and sensorial characterization of red wine aged in various types of wood barrels.

884-35-5

Post Buying Request

884-35-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

884-35-5 Usage

Uses

Used in Wine Industry:
Methyl syringate is used as a volatile compound in the wine industry for enhancing the sensorial characteristics of red wine aged in cherry, chestnut, false acacia, ash, and oak wood barrels. Its presence contributes to the distinct aroma and flavor profile of the wine, making it an essential component in the aging process.

Check Digit Verification of cas no

The CAS Registry Mumber 884-35-5 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 8,8 and 4 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 884-35:
(5*8)+(4*8)+(3*4)+(2*3)+(1*5)=95
95 % 10 = 5
So 884-35-5 is a valid CAS Registry Number.
InChI:InChI=1/C10H12O5/c1-13-7-4-6(10(12)15-3)5-8(14-2)9(7)11/h4-5,11H,1-3H3

884-35-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name methyl syringate

1.2 Other means of identification

Product number -
Other names Methyl Syringate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:884-35-5 SDS

884-35-5Synthetic route

methanol
67-56-1

methanol

3,5-dimethoxy-4-hydroxybenzoic acid
530-57-4

3,5-dimethoxy-4-hydroxybenzoic acid

methyl syringate
884-35-5

methyl syringate

Conditions
ConditionsYield
With sulfuric acid for 6h; Reflux;100%
With sulfuric acid for 3h; Reflux;96%
With thionyl chloride at 50℃; for 18h;96%
3,4,5-trimethoxybenzoic acid methyl ester
1916-07-0

3,4,5-trimethoxybenzoic acid methyl ester

methyl syringate
884-35-5

methyl syringate

Conditions
ConditionsYield
With iodine; magnesium In diethyl ether; dichloromethane at 80℃; for 1h;100%
Stage #1: 3,4,5-trimethoxybenzoic acid methyl ester With aluminum (III) chloride In dichloromethane at 20℃;
Stage #2: With hydrogenchloride; water In dichloromethane; chloroform
98%
Stage #1: 3,4,5-trimethoxybenzoic acid methyl ester With aluminum (III) chloride In dichloromethane at 20℃;
Stage #2: With hydrogenchloride In chloroform
98%
methanol
67-56-1

methanol

4-methyl-3,5-dimethoxybenzoic acid
61040-81-1

4-methyl-3,5-dimethoxybenzoic acid

methyl syringate
884-35-5

methyl syringate

Conditions
ConditionsYield
With thionyl chloride at 0℃; Reflux;95%
methyl 4-benzyloxy-3,5-dimethoxybenzoate
27065-65-2

methyl 4-benzyloxy-3,5-dimethoxybenzoate

methyl syringate
884-35-5

methyl syringate

Conditions
ConditionsYield
With sodium tetrahydroborate; nickel(II) chloride hexahydrate In methanol at 0℃;90%
With palladium on activated charcoal; ethanol Hydrogenation;
With hydrogen; palladium on activated charcoal
methyl 4-(allyloxy)-3,5-dimethoxybenzoate
1147-85-9

methyl 4-(allyloxy)-3,5-dimethoxybenzoate

methyl syringate
884-35-5

methyl syringate

Conditions
ConditionsYield
With sodium tetrahydroborate; tetrakis(triphenylphosphine) palladium(0) In tetrahydrofuran for 2h; Ambient temperature;90%
With sodium tetrahydroborate; nickel(II) chloride hexahydrate In methanol at 0℃;88%
methyl 3,5-dimethoxy-4-methoxymethoxybenzoate

methyl 3,5-dimethoxy-4-methoxymethoxybenzoate

A

3,5-dimethoxy-4-hydroxybenzoic acid
530-57-4

3,5-dimethoxy-4-hydroxybenzoic acid

B

methyl syringate
884-35-5

methyl syringate

Conditions
ConditionsYield
With ethylene glycol at 120℃; for 1h;A 10%
B 78%
6-O-syringyl-8-O-acetyl shanzhiside methyl ester
86450-76-2

6-O-syringyl-8-O-acetyl shanzhiside methyl ester

A

methyl syringate
884-35-5

methyl syringate

B

shanzhiside methyl ester
64421-28-9

shanzhiside methyl ester

Conditions
ConditionsYield
With sodium hydroxide 1.) methanol, room temperature, 4 d; Multistep reaction;
methanol
67-56-1

methanol

6-O-syringyl-8-O-acetyl shanzhiside methyl ester
86450-76-2

6-O-syringyl-8-O-acetyl shanzhiside methyl ester

methyl syringate
884-35-5

methyl syringate

Conditions
ConditionsYield
With sodium hydroxide for 96h; Ambient temperature;
Methyl syringate 4-O-α-L-rhamnopyranoside
130774-07-1

Methyl syringate 4-O-α-L-rhamnopyranoside

methyl syringate
884-35-5

methyl syringate

Conditions
ConditionsYield
With hydrogenchloride In 1,4-dioxane; water for 1h; Heating;15 mg
6-O-syringyl-8-O-acetyl shanzhiside methyl ester
86450-76-2

6-O-syringyl-8-O-acetyl shanzhiside methyl ester

A

methyl syringate
884-35-5

methyl syringate

B

shanzhiside
29836-27-9

shanzhiside

Conditions
ConditionsYield
With sodium hydroxide In methanol Ambient temperature;
hydrogenchloride
7647-01-0

hydrogenchloride

methanol
67-56-1

methanol

O-acetylsyringic acid
6318-20-3

O-acetylsyringic acid

methyl syringate
884-35-5

methyl syringate

2-Methoxyhydroquinone 4-O-<6-O-(4-O-α-L-rhamnopyranosyl)-syringyl>-β-D-glucopyranoside
136112-50-0

2-Methoxyhydroquinone 4-O-<6-O-(4-O-α-L-rhamnopyranosyl)-syringyl>-β-D-glucopyranoside

methyl syringate
884-35-5

methyl syringate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 59 mg / K2CO3 / Ambient temperature
2: 15 mg / aq. HCl / dioxane; H2O / 1 h / Heating
View Scheme
Coniferin 6'-O-(4-O-α-L-rhamnopyranosyl)-syringate

Coniferin 6'-O-(4-O-α-L-rhamnopyranosyl)-syringate

methyl syringate
884-35-5

methyl syringate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 52 mg / K2CO3 / 0.5 h / Ambient temperature
2: 15 mg / aq. HCl / dioxane; H2O / 1 h / Heating
View Scheme
Eudesmic acid
118-41-2

Eudesmic acid

methyl syringate
884-35-5

methyl syringate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: concentrated hydrochloric acid / im geschlossenen Rohr
2: HCl
View Scheme
Multi-step reaction with 2 steps
1: sulfuric acid / 24 h / Reflux; Inert atmosphere
2: boron trichloride / dichloromethane / 30 h / -10 - 20 °C / Inert atmosphere
View Scheme

884-35-5Relevant academic research and scientific papers

CHRYSOPHAENTIN ANALOGS AND USE THEREOF

-

Paragraph 00138, (2020/10/21)

Provided are 9-dechlorochrysophaentin analog compounds and the synthesis process thereof. The disclosed compound have remarkable antimicrobial activitivies that are comparable to, or even more potent than, the natural product chrysophaentin A. Also provided are method of inhibiting bacterial growth or treating bacterial infection by administering an effective amount of the disclosed compounds.

A synthetic approach to chrysophaentin F

Vendeville, Jean-Baptiste,Matters, Rebecca F.,Chen, Anqi,Light, Mark E.,Tizzard, Graham J.,Chai, Christina L. L.,Harrowven, David C.

supporting information, p. 4837 - 4840 (2019/05/02)

The chrysophaentins are a newly discovered natural product family displaying promising anti-infective activity. Herein we describe an approach to chrysophaentin F that uses an array of metal catalysed coupling reactions (Cu, Ni, Pd, W, Mo) to form key bonds.

Antifungal activity of cinnamic acid and benzoic acid esters against Candida albicans strains

Lima, Tamires C.,Ferreira, Alana R.,Silva, Daniele F.,Lima, Edeltrudes O.,de Sousa, Dami?o P.

, p. 572 - 575 (2017/09/30)

Candida albicans is an important opportunistic fungal pathogen capable of provoking infection in humans. In the present study, we evaluated the antifungal effect of 23 ester derivatives of the cinnamic and benzoic acids against 3 C. albicans strains (ATCC-76645, LM-106 and LM-23), as well as discuss their Structure–Activity Relationship (SAR). The antifungal assay results revealed that the screened compounds exhibited different levels of activity depending on structural variation. Among the ester analogues, methyl caffeate (5) and methyl 2-nitrocinnamate (10) were the analogues that presented the best antifungal effect against all C. albicans strains, presenting the same MIC values (MIC?=?128?μg/mL), followed by methyl biphenyl-2-carboxylate (21) (MIC?=?128, 128 and 256?μg/mL for C. albicans LM-106, LM-23, and ATCC-76645, respectively). Our results suggest that certain molecular characteristics are important for the antifungal action.

Composition FOR PREVENTING ALOPECIA AND ACTIVATING HAIR GROWTH

-

Paragraph 0203; 0204, (2018/02/16)

The present invention provides a hair growth promoter comprising as an active ingredient, a compound having a chemical structure of general formula (1) or a pharmacologically acceptable salt thereof. In the general formula (1): R_1 is a saturated or unsaturated straight chain or branched C1-C10 alkyl group or hydroxy alkyl group; R_2 is hydrogen or a saturated or unsaturated straight chain or branched C1-C10 alkoxy or hydroxy alkoxy; X is hydrogen, hydroxy, or a saturated or unsaturated straight chain or branched C1-C10 alkyl group, alkoxy or hydroxyl alkoxy; R_3 and R_4 are each independently selected from R_5, hydrogen, aldehyde, and a saturated or unsaturated straight chain or branched alkyl, alkoxy, or hydroxy alkoxy; R_5 has a structure of # AAA #; R_6 is selected from hydrogen, and a saturated or unsaturated straight chain or branched C1-C10 alkyl, alkoxy, or hydroxy alkoxy; and one of R_3 and R_4 is hydrogen.COPYRIGHT KIPO 2017

Partially bio-based poly(amide imide)s by polycondensation of aromatic diacylhydrazides based on lignin-derived phenolic acids and aromatic dianhydrides: Synthesis, characterization, and computational studies

Kuhire, Sachin S.,Sharma, Pragati,Chakrabarty, Suman,Wadgaonkar, Prakash P.

, p. 3636 - 3645 (2017/10/31)

Two new bio-based diacylhydrazide monomers, namely, 4,4′-(propane-1,3-diylbis(oxy))bis(3-methoxybenzohydrazide) and 4,4′-(propane-1,3-diylbis(oxy))bis(3,5-dimethoxybenzohydrazide) were synthesized starting from lignin-derived phenolic acids, namely, vanillic acid and syringic acid. A series of poly(amide imide)s was synthesized by polycondensation of these diacylhydrazide monomers with commercially available aromatic dianhydrides. Poly(amide imide)s showed inherent viscosity in the range 0.44–0.56 dL?g?1 and exhibited good solubility in organic solvents. Poly(amide imide)s could be cast into transparent, flexible, and tough films from their N,N-dimethylacetamide solutions. Poly(amide imide)s showed 10% weight loss in the temperature range 340–364?°C indicating their good thermal stability. Glass transition temperature (Tg) of poly(amide imides)s were measured by DSC and DMA which were in the range 201–223?°C and 214–248?°C, respectively. The Tg values of poly(amide imide)s were dependent on the number methoxy substituents on aromatic rings of diacylhydrazide monomers. Molecular dynamics simulation studies revealed that chain rigidity is the dominant factor for observed trends in Tg.

Method for selective demethylation of ortho-trimethoxybenzene compounds

-

Paragraph 6, (2017/04/03)

The invention relates to a method for selective demethylation of ortho-trimethoxybenzene compounds and provides a method for preparation of 2,6-dimethoxyphenol derivatives by selective demethylation of ortho-trimethoxybenzene in different substitution types. By taking substitutional or non-substitutional ortho-trimethoxybenzene as a raw material, taking ZrCl4 as a catalyst and taking anisole as an additive, a ratio of the raw material to the catalyst to the additive is optimized in a reaction process to realize selective demethylation at a low reaction temperature ranging from the room temperature to 60 DEG C. The method has the advantages of mild reaction conditions, safety, reliability, low cost and easiness in operation and acquisition of the additive and the catalyst for reaction, simplicity and easiness in separation of reaction products, wide substrate application range and the like. The method effectively improves reaction safety and controllability and has an extensive application prospect in preparation of medicines, material intermediates and fine chemicals.

Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells

Liao, Yi,Niu, Xiaojia,Chen, Bailing,Edwards, Holly,Xu, Liping,Xie, Chengzhi,Lin, Hai,Polin, Lisa,Taub, Jeffrey W.,Ge, Yubin,Qin, Zhihui

, p. 7974 - 7990 (2016/09/23)

Synergistic-to-additive antileukemic interactions of piperlongumine (PL) and HDAC inhibitor (HDACi) SAHA (Vorinostat) provide a compelling rationale to construct PL-HDACi hybrids, such as 1-58, which recapitulated the synergism between the parental compounds in high-risk and chemoresistant AML cells. Both PL and HDACi components, either in combination or in hybrid molecules, are essential for inducing significant DNA damage and apoptosis. Introducing C2-chloro substituent to 1-58 yielded 3-35 with increased cytotoxicity but decreased selectivity in noncancerous MCF-10A cells; eliminating C7-C8 olefin of PL obtained 3-31/3-98 scaffolds which were still more active than PL or SAHA in AML and were well-tolerated by MCF-10A cells. The HDACi function was crucial for modulating expression of DNA repair and apoptosis-related proteins. Collectively, PL and SAHA hybrids are potent, multifunctional anti-AML agents, acting in part, by interfering cellular GSH defense, suppressing expression of DNA repair and pro-survival proteins, and inducing expression of pro-apoptotic proteins.

NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF

-

Paragraph 0063-0064, (2014/10/16)

Disclosed are a novel benzamide derivative and pharmaceutical use thereof, and more particularly, a novel benzamide derivative having a structure of Formula 1 or pharmaceutically acceptable salts thereof, and a composition for prevention or treatment of pain or itching including the above material. The novel benzamide derivative and pharmaceutically acceptable salt thereof according to the present invention exhibit excellent pain-suppressive effect and, in particular, pain-suppressive effect in not only a neuropathic animal model but also other models such as a formalin model, and therefore, may be used in suppression of different pains such as nociceptive pain, chronic pain, etc. Further, since it was demonstrated that the present invention displays anti-pruritic efficacy even in an itching model, to which a mechanism and treatment concept established with respect to pain is applied, the present invention may also be effectively used in radical treatment of atopic dermatitis by applying the inventive product to an anti-pruritic composition in order to suppress an initial itching stage and treat symptoms thereof, thus preventing skin damage or inflammation after the scratching stage.

NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF

-

Paragraph 0095 - 0098; 0116 - 0119, (2014/11/27)

Disclosed are a novel benzamide derivative and pharmaceutical use thereof, and more particularly, a novel benzamide derivative having a structure of Formula 1 or pharmaceutically acceptable salts thereof, and a composition for prevention or treatment of pain or itching including the above material. The novel benzamide derivative and pharmaceutically acceptable salt thereof according to the present invention exhibit excellent pain-suppressive effect and, in particular, pain-suppressive effect in not only a neuropathic animal model but also other models such as a formalin model, and therefore, may be used in suppression of different pains such as nociceptive pain, chronic pain, etc. Further, since it was demonstrated that the present invention displays anti-pruritic efficacy even in an itching model, to which a mechanism and treatment concept established with respect to pain is applied, the present invention may also be effectively used in radical treatment of atopic dermatitis by applying the inventive product to an anti-pruritic composition in order to suppress an initial itching stage and treat symptoms thereof, thus preventing skin damage or inflammation after the scratching stage.

Synthesis of leptosin, a glycoside isolated from mānuka honey

Aitken, Harry R.M.,Johannes, Manuel,Loomes, Kerry M.,Brimble, Margaret A.

supporting information, p. 6916 - 6919 (2019/04/10)

The first synthesis of leptosin, a novel glycoside isolated from mānuka honey is described. Utilising an acetyl protecting group strategy the glycoside was obtained with excellent anomeric selectivity by deploying a Schmidt glycosylation as a key step.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 884-35-5